A multi-centre, randomised, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes .
Phase of Trial: Phase II/III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Vildagliptin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 May 2012 Actual patient number 1988 added as reported by ClinicalTrials.gov.
- 31 Mar 2012 Actual end date (2 Jun 2011) added as reported by European Clinical Trials Database.